secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0002007919-25-000057
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx Q1 net loss $43.3M; cash $216.5M after $100M loan; data readouts expected in 2025
--------------------------------------------------------------------------------

- Net loss $43.3M ($2.80/share) vs $78.7M ($5.77/share) in Q1 2024.
- Cash $216.5M at March 31, 2025, up from $152.6M after $100M loan from Oxford Finance in Jan 2025.
- INBRX-109 registration-enabling Phase 2 data for chondrosarcoma expected Q3 2025; CRC cohort data also Q3 2025.
- INBRX-106 Phase 2/3 data for HNSCC with Keytruda expected Q4 2025; interim NSCLC data Q4 2025.
- R&D expenses fell to $36.9M from $63.9M due to spin-off of INBRX-101 program in Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000057/0002007919-25-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000057/inhibrx-20250514.htm
  HTML page:      https://secwatch.observer/filing/0002007919-25-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer